Novabridge Biosciences (NBP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NBP Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Novabridge Biosciences adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash & cash equivalent210.63
Short-term Investments, Total0.21
Cash & Short-term Investments210.00
Other Receivables0.01
Prepaid Expense And Other Assets Current6.68
Total Current Assets217.52
Equipment/Property/Plant Net0.14
Long-term investments0.00
Other Assets, Noncurrent42.86
Total Assets260.52
Liabilities
Accounts Payable and Accrued Liabilities, Current LI16.82
Accrued Liabilities, Current2.78
Other Liabilities, Current9.18
Total Current Liabilities26.89
Total Long-term Debt0.00
Accrued Income Taxes, Noncurrent0.66
Other liabilities, Noncurrent0.51
Total Liabilities29.58
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock1,526.72
Retained Earnings / Accumulated Deficit-1,332.31
Accumulated Other Comprehensive Income41.55
Other Equity41.55
Common Stockholder's Equity273.01
Total Stockholder's Equity230.94
Liabilities & Stockholder's Equity260.52
4 historic quarters locked

Sign in to unlock the full Novabridge Biosciences balance sheet history.

About Novabridge Biosciences Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: April 7, 2026
  • Source: nbp-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001778016-26-000002

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.